TheraRadar
← Back
Data updated: Jun 28, 2026

GD SEARLE LLC

Big Pharma

GD SEARLE LLC is a major pharmaceutical company focused on Immunology.

1940
Since
28
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules

GD SEARLE LLC's Key Drugs

GD SEARLE LLC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

GD SEARLE LLC's Recent FDA Approvals

New NDA/BLA approvals for GD SEARLE LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

GD SEARLE LLC's Therapeutic Areas

GD SEARLE LLC's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 100%
1 drugs

GD SEARLE LLC's Top Competitors

GD SEARLE LLC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

GD SEARLE LLC Pipeline Snapshot

Active clinical trials for GD SEARLE LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling